for people ages 18 years and up (full criteria)
at UC Davis UC Irvine UCSF
study started
estimated completion
Principal Investigator
Sai-Hong Ignatius Ou, MD (uci)Jonathan Riess, MD (ucdavis)Caroline McCoach, MD (ucsf)
Photo of Caroline McCoach
Caroline McCoach



The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific genomic aberrations and to identify the recommended Phase 2 dose (RP2D).

Official Title

A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed/Refractory Solid Tumors With Specific Genomic Aberrations


This open-label, phase 1b/2 dose-escalation and dose-expansion study is designed to evaluate the safety and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of RMC-4630 in combination with cobimetinib in participants with relapsed/refractory solid tumors.


Solid Tumor SHP2 PTPN11 NSCLC KRAS G12 BRAF Class 3 NF1 LOF KRAS amplification KRAS mutations advanced solid tumor advanced solid malignancies melanoma skin cancer ovarian cancer pancreatic cancer endometrium/uterus cancer bladder cancer cervical cancer carcinoma, non-small-cell lung neoplasm, squamous cell carcinoma, squamous cell esophageal neoplasms carcinoma, bronchogenic bronchial neoplasms lung neoplasms respiratory tract neoplasms thoracic neoplasms neoplasms by site neoplasms lung diseases respiratory tract diseases RMC-4630 Cobimetinib RMC-4630 and Cobimetinib


You can join if…

Open to people ages 18 years and up

  • Age ≥18 years
  • Participants who have advanced solid tumors that have failed, are intolerant to, or are considered ineligible for standard of care anti-cancer treatments including approved drugs for oncogenic drivers in their tumor type.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
  • Participants must have one of the following genotypic aberrations: KRAS mutations and amplifications, BRAF Class 3 mutations, or NF1 LOF mutations
  • Adequate hematological, hepatic, and renal function
  • Capable of giving signed informed consent form (ICF). Willing and able to compile with study requirements and restrictions
  • Life expectancy >12 weeks
  • Female of childbearing potential and males with partners of childbearing potential must comply with effective contraception criteria .

You CAN'T join if...

  • Primary central nervous system (CNS) tumors.
  • Known or suspected leptomeningeal or brain metastases or spinal cord compression.
  • Clinically significant cardiac disease
  • Active, clinically significant interstitial lung disease or pneumonitis
  • History or current evidence of retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vein occlusion (RVO), or predisposing factors to RPED or RVO
  • Known HIV infection or active/chronic hepatitis B or C infection.
  • Any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
  • Females who are pregnant or breastfeeding


  • UC Irvine - Chao Family Comprehensive Cancer Center accepting new patients
    Orange California 92868 United States
  • UC Davis Comprehensive Cancer Center accepting new patients
    Sacramento California 95817 United States
  • UC San Francisco - Helen Diller Family Comprehensive Cancer Center accepting new patients
    San Francisco California 94115 United States

Lead Scientists at UC Cancer

  • Sai-Hong Ignatius Ou, MD (uci)
    Health Sciences Professor, Medicine. Authored (or co-authored) 5 research publications.
  • Jonathan Riess, MD (ucdavis)
    Assistant Professor, Hematology and Oncology. Authored (or co-authored) 62 research publications.
  • Caroline McCoach, MD (ucsf)
    Caroline McCoach is a thoracic oncologist who focuses on the treatment of patients with lung cancer as well as other thoracic malignancies. Her goal is to provide a personalized approach to treatment, based on each patient’s cancer type in combination with their individual treatment goals.


accepting new patients
Start Date
Completion Date
Revolution Medicines, Inc.
Phase 1/2
Study Type
Last Updated